Navigation Links
Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2012
Date:7/25/2012

guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms  "could," "believe,"  "outlook," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of global economic conditions; the impact of  the 2010 federal health care legislation (including excise taxes on medical devices) and any further health care reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges associated with the successful commercialization of the company's particle therapy business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future eve
'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
2. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
3. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
4. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
5. Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. PhytoSPHERE Systems, a Medical Marijuana Inc Portfolio Company, to Bring Production Facilities to Europe through Canipa Holdings.
9. New White Paper, "Five Biggest Myths about Medical Products Outsourcing," Finds OEMs Concerns are Often Unfounded
10. Winner Medical Enters into Definitive Merger Agreement with Winner Holding Limited
11. No Medical Degree Necessary: An Easy Guide to Understanding Your Probiotic Supplement Label
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... PITTSBURGH, April 13, 2012 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has received final approval from the U.S. ... Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg ... Lescol ® Capsules. This product is indicated for ...
... Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... participating in the Bank of America Merrill Lynch 2012 Health ... Nevada, on May 16, 2012, at 10:00 a.m. Pacific Time. ... be accessed via Zimmer,s Investor Relations website at http://investor.zimmer.com ...
Cached Medicine Technology:Mylan Launches First Generic Version of LescolĀ® Capsules 2Zimmer Holdings to Present at the Bank of America Merrill Lynch 2012 Health Care Conference 2
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
... NATIONAL SMOKE OUT WEEK, SOUTH FLORIDA NOVEMBER 20, 2008, ... Kirsten Haglund will be in the Sunshine State to promote,National Smoke ... Americans get healthier and kick the smoking habit., -- ... AND NEWSPAPER INTERVIEWS FROM NOVEMBER 15-17 ...
... to take helm on January 1, DALLAS, Nov. ... Executive Officer of the American Heart Association,effective January 1, ... national Board of Directors at its meeting on Wednesday.,Brown ... the association. She,succeeds Cass Wheeler, who has served as ...
... sufferers non-drug option for symptom relief -, ... Annual Symposium on,Intestinal Flora at Yakult World Headquarters ... from 19 countries, including,the U.S. This year,s theme, ... interactions and Irritable,Bowel Syndrome, which is believed to ...
... 3 Rib-X Pharmaceuticals, Inc.,("Rib-X" or the "Company"), ... of novel antibiotics for the treatment of,antibiotic-resistant infections, ... Executive Officer, is scheduled to present at the,Rodman ... November 10,2008 at 2:00pm EST. The conference will ...
... Highlights ... - Gross margin expanded to 32.4 ... - Health management segment revenue grew 25 percent, - ... MINNEAPOLIS, Nov. 3 Health Fitness,Corporation (NYSE Alternext US: FIT), a ...
... lead has eroded since previous poll, Democratic contender,still ... 3 In the waning days of the,2008 ... (D-Ill.) over Sen. John McCain (R-Ariz.) by a ... MedPage Today, LLC, (http://www.MedPageToday.com )., (Photo: ...
Cached Medicine News:Health News:Brown Named CEO of the American Heart Association 2Health News:Brown Named CEO of the American Heart Association 3Health News:Brown Named CEO of the American Heart Association 4Health News:Irritable Bowel Syndrome Takes Center Stage at Yakult's 17th Intestinal Flora Symposium 2Health News:Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 2Health News:HealthFitness Announces 2008 Third Quarter Results 2Health News:HealthFitness Announces 2008 Third Quarter Results 3Health News:HealthFitness Announces 2008 Third Quarter Results 4Health News:HealthFitness Announces 2008 Third Quarter Results 5Health News:HealthFitness Announces 2008 Third Quarter Results 6Health News:HealthFitness Announces 2008 Third Quarter Results 7Health News:HealthFitness Announces 2008 Third Quarter Results 8Health News:HealthFitness Announces 2008 Third Quarter Results 9Health News:HealthFitness Announces 2008 Third Quarter Results 10Health News:Election-Eve MedPage Today(R) Poll Gives Obama Double-Digit Lead Among Clinicians 2Health News:Election-Eve MedPage Today(R) Poll Gives Obama Double-Digit Lead Among Clinicians 3
... Multiple blood chemistry testing. One-step testing. Average ... thirty day. Storage of up to 250 ... Automatic shut-off in two minutes from non-use ... Chip (included with each strip package). Results ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
... ACON Strep A Twist Rapid Test Device (Throat ... format, utilizing a patented design to provide convenience ... a built-in swab chamber, eliminating the need for ... This test exhibits a 93% accuracy compared to ...
... System offers unparalleld speed, providing accurate, ... requiring only 10 ul of blood. ... more comprehensive patient care by spending ... CoaguChek S System is easy-to-use, accurate, ...
Medicine Products: